HUP0300418A2 - Eljárás klaritromicin (II) típusú kristálymódosulatainak az előállítására - Google Patents

Eljárás klaritromicin (II) típusú kristálymódosulatainak az előállítására

Info

Publication number
HUP0300418A2
HUP0300418A2 HU0300418A HUP0300418A HUP0300418A2 HU P0300418 A2 HUP0300418 A2 HU P0300418A2 HU 0300418 A HU0300418 A HU 0300418A HU P0300418 A HUP0300418 A HU P0300418A HU P0300418 A2 HUP0300418 A2 HU P0300418A2
Authority
HU
Hungary
Prior art keywords
clarithromycin
water
crystalline
formula
organic solvent
Prior art date
Application number
HU0300418A
Other languages
English (en)
Inventor
Gi Jeong Kim
Nam Du Kim
Gwan Sun Lee
Mi Ra Seong
Kwee Hyun Suh
Sang Min Yun
Original Assignee
Hanmi Pharm Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020000013033A external-priority patent/KR100361397B1/ko
Priority claimed from KR10-2000-0069834A external-priority patent/KR100367981B1/ko
Application filed by Hanmi Pharm Co., Ltd. filed Critical Hanmi Pharm Co., Ltd.
Publication of HUP0300418A2 publication Critical patent/HUP0300418A2/hu
Publication of HUP0300418A3 publication Critical patent/HUP0300418A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

A találmány tárgya eljárás (I) képletű, (II) kristálymódosulatúklaritromicin előállítására, amely szerint (a) nem gyógyszerészetiminőségű klaritromicint metánszulfonsavval kezelnek vízzel elegyedőszerves oldószer és víz keverékében (II) képletű, kristályosklaritromicin-mezilát-trihidrát előállítására; és (b) a kapottkristályos klaritromicin-mezilát-trihidrátot vizes ammóniávalsemlegesítik vízzel elegyedő szerves oldószer és víz keverékében; ahola nem gyógyszerészeti minőségű klaritromicin bármilyen tisztaságú vagybármilyen kristályosságú klaritromicnt jelent, beleértve azelőállítási eljárás során kapott nyersterméket is. Ó
HU0300418A 2000-03-15 2001-03-14 Method of preparing clarithromycin of form ii crystals HUP0300418A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020000013033A KR100361397B1 (ko) 2000-03-15 2000-03-15 에리스로마이신 에이 9-오-트로필옥심 유도체를 이용한클라리스로마이신의 제조방법
KR10-2000-0069834A KR100367981B1 (ko) 2000-11-23 2000-11-23 클라리스로마이신 결정형 2의 제조 방법 및 이 방법에사용되는 결정성 클라리스로마이신 메실레이트 삼수화물
PCT/KR2001/000394 WO2001068662A1 (en) 2000-03-15 2001-03-14 Method of preparing clarithromycin of form ii crystals

Publications (2)

Publication Number Publication Date
HUP0300418A2 true HUP0300418A2 (hu) 2003-06-28
HUP0300418A3 HUP0300418A3 (en) 2003-09-29

Family

ID=36274127

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300418A HUP0300418A3 (en) 2000-03-15 2001-03-14 Method of preparing clarithromycin of form ii crystals

Country Status (15)

Country Link
US (1) US6515116B2 (hu)
EP (2) EP1469008B1 (hu)
JP (1) JP4119125B2 (hu)
CN (1) CN1193036C (hu)
AT (2) ATE297941T1 (hu)
AU (1) AU771825B2 (hu)
BR (1) BR0109194A (hu)
CA (1) CA2402201C (hu)
DE (2) DE60122791T2 (hu)
ES (2) ES2270226T3 (hu)
HU (1) HUP0300418A3 (hu)
MX (1) MXPA02008861A (hu)
NZ (1) NZ521184A (hu)
RU (1) RU2230748C2 (hu)
WO (1) WO2001068662A1 (hu)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
EP1313486A1 (en) * 2000-02-29 2003-05-28 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
KR100367981B1 (ko) * 2000-11-23 2003-01-14 한미약품공업 주식회사 클라리스로마이신 결정형 2의 제조 방법 및 이 방법에사용되는 결정성 클라리스로마이신 메실레이트 삼수화물
BR0109544A (pt) * 2000-03-28 2003-06-10 Biochemie Gmbh Partìculas granuladas com sabor ocultado
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
US20060083759A1 (en) * 2002-07-17 2006-04-20 Aleksander Resman Stabilization of the profile of release of active substances from a formulation
CA2529817C (en) 2003-03-10 2013-02-12 Optimer Pharmaceuticals, Inc. Novel antibacterial agents
ES2221807B1 (es) * 2003-06-24 2005-12-16 Ercros Industrial, S.A. Un procedimiento para la obtencion de claritromicina.
US8313776B2 (en) * 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
JP2006528185A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
JP2006528190A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
CA2535177A1 (en) * 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
CA2535398C (en) * 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
AU2004270170B2 (en) * 2003-08-29 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
WO2005027877A1 (en) * 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
JP2008505124A (ja) * 2004-07-02 2008-02-21 アドバンシス ファーマスーティカル コーポレイション パルス送達用錠剤
CN101073284B (zh) * 2005-02-07 2010-05-05 中兴通讯股份有限公司 一种控制系统间测量和频间测量的方法
WO2007015265A2 (en) * 2005-05-24 2007-02-08 Kopran Research Laboratories Ltd A process for preparing 6,9-imino ether
WO2007008537A2 (en) * 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
WO2007036951A2 (en) * 2005-08-31 2007-04-05 Alembic Limited Process to obtain 6-o-methylerythromycin a (clarithromycin)_form ii
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
EP2030613A1 (en) 2007-08-17 2009-03-04 Abbott GmbH & Co. KG Preparation of compositions with essentially noncrystalline embedded macrolide antibiotics
JP5698979B2 (ja) 2007-10-25 2015-04-08 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライド系抗菌剤の調製プロセス
JP5602748B2 (ja) 2008-10-24 2014-10-08 センプラ ファーマシューティカルズ，インコーポレイテッド トリアゾール含有マクロライドを用いた生体防御
CN101787063B (zh) * 2009-01-23 2012-12-19 刘力 抗感染药物及其制备和用途
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
ES2608285T3 (es) 2009-09-10 2017-04-07 Cempra Pharmaceuticals, Inc. Procedimientos para el tratamiento de paludismo, tuberculosis y enfermedades por MAC
DK2550286T3 (en) 2010-03-22 2016-02-29 Cempra Pharmaceuticals Inc CRYSTALLINE FORMS OF A MACROLID AND APPLICATIONS THEREOF
BR112012029586A2 (pt) 2010-05-20 2016-08-02 Cempra Pharmaceuticals Inc processos para preparar macrolídeos e cetolídeos e intermediários dos mesmos
JP6042334B2 (ja) 2010-09-10 2016-12-14 センプラ ファーマシューティカルズ，インコーポレイテッド 疾患治療のための水素結合形成フルオロケトライド
US10188674B2 (en) 2012-03-27 2019-01-29 Cempra Pharmaceuticals, Inc. Parenteral formulations for administering macrolide antibiotics
CN103897002A (zh) * 2012-12-31 2014-07-02 菏泽市方明制药有限公司 一种粗品硫氰酸红霉素制备红霉素a9-肟的方法
CN103087130B (zh) * 2013-02-06 2015-12-23 浙江国邦药业有限公司 一种克拉霉素晶型转换方法
JP6426696B2 (ja) 2013-03-14 2018-11-21 センプラ ファーマシューティカルズ，インコーポレイテッド 呼吸器疾患の治療のための方法および製剤
US9751908B2 (en) 2013-03-15 2017-09-05 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60214796A (ja) * 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシン類の製法
US4670549A (en) * 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
KR960000434B1 (ko) * 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
US5872229A (en) * 1995-11-21 1999-02-16 Abbott Laboratories Process for 6-O-alkylation of erythromycin derivatives
US5837829A (en) * 1996-04-02 1998-11-17 Abbott Laboratories 9-oximesilyl erythromycin a derivatives
US5858986A (en) * 1996-07-29 1999-01-12 Abbott Laboratories Crystal form I of clarithromycin
DK0915899T3 (da) * 1996-07-29 2004-11-29 Abbott Lab Fremstilling af krystallinsk form II af clarithromycin
US5945405A (en) * 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
US5864023A (en) * 1997-02-13 1999-01-26 Abbott Laboratories 3'-N'oxide, 3'-n-dimethylamine, 9-oxime erythromycin a derivatives
IL135792A0 (en) * 1997-12-01 2001-05-20 Abbott Lab 6-o-alkyl derivatives of erythronolide b
US6258785B1 (en) * 1998-12-02 2001-07-10 Pfizer Inc. Crystalline 9-E-(O-methyl)oxime of 11, 12-dideoxy-3-de(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribohexopyranosyloxy)-6-O-methyl-12,11-(iminocarbonyl-(2-(3-(4-(3-pyridinyl)1H-imadazol-1-yl)propyl)hydrazono))-3-oxoerythromycin

Also Published As

Publication number Publication date
DE60111438D1 (de) 2005-07-21
AU4282701A (en) 2001-09-24
HUP0300418A3 (en) 2003-09-29
EP1134229A3 (en) 2002-02-27
ES2270226T3 (es) 2007-04-01
CA2402201C (en) 2007-06-05
CN1193036C (zh) 2005-03-16
NZ521184A (en) 2004-02-27
US6515116B2 (en) 2003-02-04
CN1429233A (zh) 2003-07-09
JP4119125B2 (ja) 2008-07-16
ATE297941T1 (de) 2005-07-15
EP1134229A2 (en) 2001-09-19
DE60122791D1 (de) 2006-10-12
ES2242668T3 (es) 2005-11-16
BR0109194A (pt) 2003-02-11
RU2230748C2 (ru) 2004-06-20
DE60122791T2 (de) 2007-10-04
DE60111438T2 (de) 2006-05-18
MXPA02008861A (es) 2003-02-10
EP1469008B1 (en) 2006-08-30
US20010039333A1 (en) 2001-11-08
EP1469008A1 (en) 2004-10-20
RU2002127591A (ru) 2004-02-27
CA2402201A1 (en) 2001-09-20
WO2001068662A1 (en) 2001-09-20
AU771825B2 (en) 2004-04-01
JP2004500398A (ja) 2004-01-08
EP1134229B1 (en) 2005-06-15
ATE338053T1 (de) 2006-09-15

Similar Documents

Publication Publication Date Title
HUP0300418A2 (hu) Eljárás klaritromicin (II) típusú kristálymódosulatainak az előállítására
TW200510439A (en) Improved crystalline form of sucralose, and method for producing it
TW331561B (en) Production of sucralose without intermediate isolation of crystalline sucralose-6-ester
UA95598C2 (ru) Способ получения оптически активных аминопроизводных
AP1709A (en) Ethanolate of azithromycin, process for manufacure, and pharmaceutical compositions thereof.
TNSN04044A1 (en) Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations
HUP0004325A2 (hu) 2-(3-Ciano-4-izobutiloxifenil)-4-metil-5-tiazolkarbonsav polimorf módosulatai és eljárás ezek előállítására
WO2001030773A3 (en) Lactonization process
TW200604100A (en) A method for producing an α-alumina powder
EP0908523A3 (en) Process for producing high-purity erythritol crystal
HUP9900550A2 (hu) Eljárás azithromicin-dihidrát előállítására
HUP0402112A2 (hu) Eljárás kristályos imipenem előállítására
EP1318201A4 (en) PROCESS FOR PRODUCING PURIFIED ANTHOCYANIN AND CRYSTALLINE ANTHOCYANIN
WO2001085412A3 (en) Production process of high-purity gypsum
MY126071A (en) Crystalline form ii of cabergoline.
GB651643A (en) Improvements in or relating to the production of glutamic acid and betaine hydrochloride
EP1447409A4 (en) CRYSTAL OF OXIDIZED GLUTATHION AND METHOD FOR THE PRODUCTION THEREOF
CA2471730A1 (en) Process for preparing and purifying 1,7'-dimethyl-2'-propyl-2,5'-bi-1h-benzimidazole
EP1334962A4 (en) PROCESS FOR THE PREPARATION OF ACYLPHENYLALANINES
ATE486867T1 (de) Verfahren zur herstellung von hochreinem meloxicam und meloxicam-kaliumsalz
DK1187805T3 (da) Fremgangsmåde til fremstilling af R-(-)-carnitin ud fra S-(-)-chlorravsyre eller ud fra et derivat deraf
ATE329900T1 (de) Verfahren zur herstellung von 2-pyrrolidon
ES2033175A1 (es) Obtencion en continuo de sales fertilizantes con derivados de estroncio y yeso.
JP2000086616A (ja) クレアチンまたはクレアチン一水和物の製造法
DE50101761D1 (de) Verfahren zur herstellung von 6-(4-chlorphenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1h-pyrrolizin-5-yl-essigsäure

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees